Rocket One's Hoth Therapeutics Subsidiary Plans To End Its Phase 2a Clinical Study Of HT-001 After Interim Efficacy Data; Intends To Seek FDA Feedback For Conducting HT-001 Into Potential Phase 3 Clinical Program

Rocket One Inc. (NASDAQ:RKTO) ("Rocket One" or the "Company") today announced that its biotechnology subsidiary, Hoth Therapeutics, has decided to end its Phase 2a clinical trial of HT-001 early following strong interim efficacy results. Hoth is preparing to seek U.S. Food and Drug Administration (FDA) feedback on advancing HT-001 into a potential Phase 3 clinical program.